[go: up one dir, main page]

PE20021152A1 - Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma - Google Patents

Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma

Info

Publication number
PE20021152A1
PE20021152A1 PE2002000399A PE2002000399A PE20021152A1 PE 20021152 A1 PE20021152 A1 PE 20021152A1 PE 2002000399 A PE2002000399 A PE 2002000399A PE 2002000399 A PE2002000399 A PE 2002000399A PE 20021152 A1 PE20021152 A1 PE 20021152A1
Authority
PE
Peru
Prior art keywords
agonists
proliferation
oxazole derivatives
activated receptors
peroxisome
Prior art date
Application number
PE2002000399A
Other languages
English (en)
Inventor
Alfred Binggeli
Markus Boehringer
Uwe Grether
Fabienne Ricklin
Hans-Peter Maerki
Markus Meyer
Peter Mohr
Hans Hilpert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20021152A1 publication Critical patent/PE20021152A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A DERIVADOS DE OXAZOL DE FORMULA I DONDE R1 ES ARILO, HETEROARILO; R2, R3, R4, R6 SON H, OH, ALQUENILO, HALOGENO, ALQUILO, ALCOXILO; AL MENOS UNO DE R2, R3, R4, R6 NO ES H; O R3 Y R4 JUNTOS FORMAN UN ANILLO O SON -CH=CH-S-, -S-CH=CH, ENTRE OTROS; R5 ES ALCOXILO, ALQUENILOXILO, GRUPO a, b; R7, R8, R9 SON H, ALQUILO; R10 ES ARILO; n ES 1-3. SON COMPUESTOS PREFERIDOS ACIDO 2-METOXI-3-{4-[2-(5-METIL-2-FENIL-OXAZOL-4-IL)-ETOXI]-BENZO[b]TIOFEN-7-IL}-PROPIONICO; ACIDO 3-{4-[2-(5-METIL-2-FENIL-OXAZOL-4-IL)-ETOXI]-BENZO[b]TIOFEN-7-IL}-2-PROPOXI-PROPIONICO; ENTRE OTROS; TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON AGONISTAS DE RECEPTORES ACTIVADOS DE LA PROLIFERACION DEL PEROXISOMA COMBINANDO EL EFECTO ANTIGLICEMICO DE LA ACTIVACION DE PPARGAMMA CON EL EFECTO ANTIDISLIPIDEMICO DE LA ACTIVACION DE PPARO Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE DIABETES, DIABETES MELLITUS NO INSULINO DEPENDIENTE, HIPERTENSION, NIVELES ALTOS DE COLESTEROL, LIPIDOS, ENFERMEDAD ARTERIOESCLEROTICA, SINDROMES METABOLICOS
PE2002000399A 2001-05-15 2002-05-14 Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma PE20021152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01111745 2001-05-15

Publications (1)

Publication Number Publication Date
PE20021152A1 true PE20021152A1 (es) 2003-02-07

Family

ID=8177436

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000399A PE20021152A1 (es) 2001-05-15 2002-05-14 Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma

Country Status (38)

Country Link
US (1) US6642389B2 (es)
EP (1) EP1392295B1 (es)
JP (2) JP4330883B2 (es)
KR (1) KR100654516B1 (es)
CN (1) CN100356917C (es)
AR (1) AR035892A1 (es)
AT (1) ATE327753T1 (es)
AU (1) AU2002342244B2 (es)
BG (1) BG66316B1 (es)
BR (1) BRPI0209821B1 (es)
CA (1) CA2445145C (es)
CY (1) CY1105160T1 (es)
CZ (1) CZ20033037A3 (es)
DE (1) DE60211891T2 (es)
DK (1) DK1392295T3 (es)
EC (1) ECSP034848A (es)
EG (1) EG25755A (es)
ES (1) ES2264482T3 (es)
GT (1) GT200200085A (es)
HR (1) HRP20030889B1 (es)
HU (1) HU230224B1 (es)
IL (2) IL158589A0 (es)
JO (1) JO2282B1 (es)
MA (1) MA27025A1 (es)
ME (1) ME01310B (es)
MX (1) MXPA03010435A (es)
MY (1) MY136761A (es)
NO (1) NO333833B1 (es)
NZ (1) NZ529033A (es)
PA (1) PA8544901A1 (es)
PE (1) PE20021152A1 (es)
PL (1) PL208074B1 (es)
PT (1) PT1392295E (es)
RU (1) RU2278859C2 (es)
SI (1) SI1392295T1 (es)
SK (1) SK287842B6 (es)
WO (1) WO2002092084A1 (es)
ZA (1) ZA200308538B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
HUP0302397A3 (en) * 2000-05-26 2007-02-28 Nippon Shinyaku Co Ltd Heterocyclic compounds and pharmaceutical compositions containing them
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
RU2278859C2 (ru) * 2001-05-15 2006-06-27 Ф.Хоффманн-Ля Рош Аг Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
WO2003013571A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
WO2003072102A1 (en) 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
CA2495942C (en) * 2002-08-30 2010-03-23 F. Hoffmann-La Roche Ag Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists
TWI343915B (en) 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
MXPA05005063A (es) * 2002-11-15 2005-08-16 Cadila Healthcare Ltd Derivados sustituidos de aralquilo.
BR0316556A (pt) 2002-11-25 2005-10-04 Hoffmann La Roche Compostos, processo para a preparação de um composto, composição farmacêutica que compreende esse composto, sua utilização e método para o tratamento e/ou profilaxia de enfermidades que são moduladas por agonistas ppar(alfa) e/ou ppary
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
FR2849849B1 (fr) 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
CA2543249C (en) 2003-11-05 2012-08-07 F. Hoffmann-La Roche Ag Phenyl derivatives as ppar agonists
CN1875001A (zh) * 2003-11-05 2006-12-06 霍夫曼-拉罗奇有限公司 作为ppar激活剂的苯并增环化合物
WO2005056536A1 (en) * 2003-12-10 2005-06-23 Ranbaxy Laboratories Limited Antidiabetic agents which exhibit activity against ppar
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
NZ550447A (en) 2004-05-03 2010-06-25 Hoffmann La Roche Hexafluoro-indolyl derivatives as liver-x-receptor modulators
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
WO2006108491A1 (en) * 2005-04-11 2006-10-19 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Improved process for preparing oxazole nitriles
US20060241073A1 (en) * 2005-04-20 2006-10-26 Wanders Ronaldus J A Means and methods for counteracting fatty acid accumulation
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
KR100847780B1 (ko) * 2006-10-26 2008-07-23 재단법인서울대학교산학협력재단 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
JP2010520873A (ja) * 2007-03-07 2010-06-17 ドン・ア・ファーム・カンパニー・リミテッド ペルオキシソーム増殖因子活性化γ受容体調節因子としての新規フェニルプロピオン酸誘導体、その方法およびそれを含む医薬組成物
DK2100604T3 (da) * 2008-03-10 2012-07-23 Nestec Sa Dicarboxylsyrer med medium kæde og deres derivater og metaboliske lidelser
WO2009140163A1 (en) * 2008-05-15 2009-11-19 Merck & Co., Inc. Oxazolobenzimidazole derivatives
WO2010072387A2 (en) 2008-12-23 2010-07-01 Roche Diagnostics Gmbh Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
WO2010084066A1 (en) * 2009-01-23 2010-07-29 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising aleglitazar
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
US8450496B2 (en) * 2009-03-24 2013-05-28 Hoffman-La Roche Inc. Process for the preparation of propionic acid derivatives
SI2585452T1 (sl) 2009-12-07 2015-12-31 F. Hoffmann-La Roche Ag Postopek za pripravo derivatov propionske kisline
CN102351852B (zh) * 2011-08-23 2014-06-18 上海交通大学 苯并呋喃类化合物及其制备方法、用途
WO2013181384A1 (en) 2012-05-31 2013-12-05 Ratiopharm Gmbh Solid state forms of aleglitazar sodium
RU2015110641A (ru) * 2012-09-12 2016-11-10 Ф. Хоффманн-Ля Рош Аг Твердые формы (s)-2-метокси-3-{4-[2-(5-метил-2-фенилоксазол-4-ил)-этокси]-бензо[b]тиофен-7-ил}-пропионовой кислоты и ее солей
WO2017084989A1 (en) 2015-11-18 2017-05-26 F. Hoffmann-La Roche Ag Aleglitazar for the treatment of diabetic kidney disease
EP3478297A1 (en) 2016-06-30 2019-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
WO2020156683A1 (en) 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar for use in the treatment or prevention of major adverse cardiac events
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
IL310176A (en) * 2021-08-13 2024-03-01 Alebund Pharmaceuticals Hong Kong Ltd Deuterated compounds
WO2024100051A1 (en) 2022-11-08 2024-05-16 Genfit Ppar-alpha/gamma agonist for use in the treatment of liver failure
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011326A (en) 1975-07-29 1977-03-08 Merck & Co., Inc. 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
RU2032677C1 (ru) * 1992-05-05 1995-04-10 Бристоль-Мейерз Сквибб Компани Производные оксазола
PL174610B1 (pl) 1992-07-03 1998-08-31 Smithkline Beecham Plc Nowe związki heterocykliczne
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
DK1027043T3 (da) 1996-12-10 2005-01-10 Bristol Myers Squibb Co Benzodioxol-, benzofuran-, dihydrobenzofuran- og benzodioxanmelatonerge midler
DE19711616A1 (de) 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en) 1997-07-14 2000-09-19 Xerox Corporation Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
ES2200248T3 (es) 1997-09-19 2004-03-01 Ssp Co., Ltd. Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen.
AU1120599A (en) 1998-04-23 1999-03-08 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
ES2258431T3 (es) 1999-08-02 2006-09-01 F. Hoffmann-La Roche Ag Proceso para la preparacion de derivados de benzotiofeno.
PT1313716E (pt) * 2000-08-23 2007-07-11 Lilly Co Eli Derivados do ácido oxazolil-arilpropiónico e a sua utilização como agonistas do ppar
RU2278859C2 (ru) * 2001-05-15 2006-06-27 Ф.Хоффманн-Ля Рош Аг Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета

Also Published As

Publication number Publication date
CA2445145A1 (en) 2002-11-21
KR100654516B1 (ko) 2006-12-05
HRP20030889B1 (hr) 2011-10-31
ZA200308538B (en) 2005-04-26
GT200200085A (es) 2003-01-16
JO2282B1 (en) 2005-09-12
CN1509173A (zh) 2004-06-30
NO333833B1 (no) 2013-09-30
IL158589A0 (en) 2004-05-12
SI1392295T1 (sl) 2006-10-31
CZ20033037A3 (cs) 2004-06-16
HUP0400992A3 (en) 2007-11-28
CN100356917C (zh) 2007-12-26
ME01310B (me) 2011-10-10
HU230224B1 (hu) 2015-10-28
DE60211891T2 (de) 2007-05-24
HRP20030889A2 (en) 2005-08-31
PL208074B1 (pl) 2011-03-31
ES2264482T3 (es) 2007-01-01
JP2009138011A (ja) 2009-06-25
MXPA03010435A (es) 2004-03-09
EP1392295A1 (en) 2004-03-03
CY1105160T1 (el) 2009-11-04
BG108362A (bg) 2005-03-31
JP4330883B2 (ja) 2009-09-16
NZ529033A (en) 2005-06-24
MY136761A (en) 2008-11-28
SK13852003A3 (en) 2004-10-05
DK1392295T3 (da) 2006-10-02
BRPI0209821B1 (pt) 2016-09-27
MA27025A1 (fr) 2004-12-20
AU2002342244B2 (en) 2005-06-16
PL367087A1 (en) 2005-02-21
RU2278859C2 (ru) 2006-06-27
KR20030096397A (ko) 2003-12-24
EP1392295B1 (en) 2006-05-31
SK287842B6 (sk) 2011-12-05
ECSP034848A (es) 2003-12-24
US20030055265A1 (en) 2003-03-20
JP2004529174A (ja) 2004-09-24
CA2445145C (en) 2008-10-14
NO20035086D0 (no) 2003-11-14
PA8544901A1 (es) 2003-01-24
US6642389B2 (en) 2003-11-04
AR035892A1 (es) 2004-07-21
BG66316B1 (bg) 2013-04-30
PT1392295E (pt) 2006-09-29
BR0209821A (pt) 2004-06-01
EG25755A (en) 2012-06-26
WO2002092084A1 (en) 2002-11-21
DE60211891D1 (de) 2006-07-06
HUP0400992A2 (hu) 2004-08-30
HK1067534A1 (en) 2005-04-15
RU2003134150A (ru) 2005-06-10
IL158589A (en) 2010-11-30
ATE327753T1 (de) 2006-06-15
NO20035086L (no) 2003-11-14

Similar Documents

Publication Publication Date Title
PE20021152A1 (es) Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma
PE20120764A1 (es) Derivados de isotiazolo-pirimidindiona como moduladores de trpa1
PE20040987A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
PE20090297A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis
PE20030989A1 (es) Derivados de tiazol y oxazol que modulan la actividad de ppar
PE20011010A1 (es) Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
PE20011056A1 (es) Acidos ariloxiaceticos para la diabetes y trastornos de los lipidos
PE20031010A1 (es) Derivados de tiazol y oxazol que modulan la actividad de ppar
PE20070854A1 (es) Compuestos heterociclos como agonistas del receptor de acido nicotinico
JP2003502369A5 (es)
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
PE20091901A1 (es) Activadores de glucoquinasa
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
ES2564010T3 (es) Composición farmacéutica para tratar o prevenir el glaucoma
WO2004063190A1 (en) Fused heterocyclic derivates as ppar modulators
PE20030134A1 (es) Derivados de oxazolidinonas como antibacterianos
RU2006119776A (ru) Производные бензо{b}{1, 4} диоксепина
PE20021158A1 (es) Derivados de sulfonamida como antagonistas del receptor de bradiquinina
AR041079A1 (es) Derivados de 2-ariltiazol como agonistas de receptores activados proliferadores de peroxisomas alfa y gamma (ppar alfa y gamma)
PE20030930A1 (es) Derivados de tiazol como antagonistas del receptor npy
PE20050293A1 (es) Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos
PE20090999A1 (es) Nuevos derivados de metil-bencimidazol
AR051514A1 (es) Derivados de pirido[2, 1 - a]isoquinolina sustituidos como inhibidores de dpp-iv; un proceso para su elaboracion; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de distintos tipos de diabetes y de intolerancia a la glucosa.
AR041481A1 (es) Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar

Legal Events

Date Code Title Description
FG Grant, registration